Omeros (OMER) EBIT Margin (2010 - 2026)

Omeros (OMER) reported EBIT Margin of 176.09% for Q1 2026, up 52.48% sequentially from 370.6% in Q2 2022.

Omeros (OMER) EBIT Margin (2010 - 2026) Analysis & Trends

Omeros (OMER) has 14 years of EBIT Margin data on file, last reported at 176.09% in Q1 2026.

For the quarter ending Q1 2026, EBIT Margin changed N/A year-over-year to 176.09%; the trailing twelve-month figure through Mar 2026 stood at 389.94% (down 64935.0% YoY), and the FY2020 full-year result was 212.59%, down 8197.0% from the prior year.
EBIT Margin rose to 176.09% in Q1 2026, from 370.6% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 176.09% in Q1 2026 to a low of 500.94% in Q1 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	-176.09%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-176.09%
Jun 30, 2022	-370.60%
Mar 31, 2022	-500.94%
Dec 31, 2021	53.69%
Sep 30, 2021	-132.74%
Jun 30, 2021	-158.24%
Mar 31, 2021	-215.04%
Dec 31, 2020	-318.06%
Sep 30, 2020	-97.37%
Jun 30, 2020	-204.58%
Mar 31, 2020	-100.59%
Dec 31, 2019	-70.93%
Sep 30, 2019	-37.18%
Jun 30, 2019	-34.90%
Mar 31, 2019	-88.34%
Dec 31, 2018	-83.91%
Sep 30, 2018	-769.14%
Jun 30, 2018	-1,849.97%
Mar 31, 2018	-1,743.64%
Dec 31, 2017	-102.62%